Pharmabiz5h
Ventus Therapeutics’ partner Novo Nordisk doses first participant in phase 1 clinical study for NNC6022-0001, an oral NLRP3 inhibitor
Ventus Therapeutics, Inc, a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE, to develop differentiated small ...
Pharmabiz5h
IADVL sets Guinness World Record for receiving 9,419 pledges to raise dermatological disease awareness in 24 hours
India’s largest organization of dermatologists, the Indian Association of Dermatologists, Venereologists, and Leprologists (IADVL), marked a significant milestone by achieving the Guinness World ...
Pharmabiz5h
UroGen Pharma highlights results of sub-analysis from first and largest real-world patient cohort review of Jelmyto for pyelocalyceal solution
UroGen Pharma Ltd, a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, highlighted the results of a sub-analysis from the first ...
Pharmabiz5h
Mediar begins patient dosing in US FDA approved phase 1 trial of MTX-463
Mediar Therapeutics, Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, announced that, following FDA clearance of its investigational new ...
Pharmabiz5h
bluebird bio completes first commercial cell collection for Lyfgenia gene therapy
bluebird bio, Inc. announced that it has completed the first commercial cell collection for Lyfgenia (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in ...
Pharmabiz5h
RedHill Biopharma’s opaganib as a therapy for Ebola virus receives Chinese patent
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced the issue of a new Chinese patent Notice of Allowance covering opaganib as a therapy for inhibition of single-stranded RNA ...
Pharmabiz12h
Naprod Life Sciences successfully renews EU-GMP certification for its Palghar facility
Naprod Life Sciences successfully renews EU-GMP certification for its Palghar facility: Our Bureau, Mumbai Tuesday, May 7, 2024, 16:30 Hrs [IST] Naprod Life Sciences has announced ...
Pharmabiz14h
Calliditas announces positive topline results from phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
Stockholm, Sweden Tuesday, May 7, 2024, 14:00 Hrs [IST] ...
Pharmabiz15h
IIHMR University has 200 healthcare start-ups from across India to come under its Saamarthya 2.O
IIHMR University has 200 healthcare start-ups from across India to come under its Saamarthya 2.O ...
Pharmabiz16h
Cipla’s Breathefree initiative works on empowerment across the care continuum this asthma awareness month in May
Cipla’s Breathefree initiative works on empowerement across the care continuum this asthma awareness month in May. The significance of effective asthma management comes into sharp focus amidst the ...
Pharmabiz16h
AstraZeneca completes equity investment agreement with Cellectis
AstraZeneca announced the successful completion of an equity investment with Cellectis, a clinical-stage biotechnology company. The equity investment and a research collaboration agreement, announced ...
Pharmabiz16h
Lupin receives US FDA approval for travoprost ophthalmic solution USP
Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for travoprost ...